Medicated IUS
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intrauterine
-
Intended Duration:
- Long-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Merck
Details
- API: Etonogestrel
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Nonspecific - Plastic
- Regimen: 1 Insertion/Undetermined Interval
- MPT: Not Potential MPT
Product Status
No publications, no additional news. Neither Merck nor Organon have shared additional information publicly.
History
Phase II studies were completed in July 2011 to test different quantities of etonogestrel (38mg, 61mg, 72mg) and different thicknesses of the reservoir's membrane (350 μm, 140 μm, and 50 μm), respectively. This work was done under authority of the European Medicines Agency.